Arbutus Biopharma (ABUS) stock Forecast for 2022 – 2026
Last update: 05-24-2022, 7:57Sector: Healthcare
The share price of Arbutus Biopharma Corp. (ABUS) now
What analysts predict:: $6.7
52-week high/low: $6.5 / $1.93
50/200 Day Moving Average: $2.71 / $3.36
This figure corresponds to the average price over the previous 50/200 days. For Arbutus Biopharma stocks, the 50-day moving average is the resistance level today.
For Arbutus Biopharma stocks, the 200-day moving average is the resistance level today.
Are you interested in Arbutus Biopharma Corp. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Arbutus Biopharma stock price in 2022, 2023, 2024, 2025, 2026. How much will one Arbutus Biopharma share be worth in 2022 - 2026?
When should I take profit in Arbutus Biopharma stock? When should I record a loss on Arbutus Biopharma stock? What are analysts' forecasts for Arbutus Biopharma stock? What is the future of Arbutus Biopharma stock?
We forecast Arbutus Biopharma stock performance using neural networks based on historical data on Arbutus Biopharma stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Arbutus Biopharma stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026)
The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Arbutus Biopharma shares. This happens once a day.
Historical and forecast chart of Arbutus Biopharma stock
The chart below shows the historical price of Arbutus Biopharma stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Arbutus Biopharma stock price can be found in the table below.
Long-term forecasts by years.
Arbutus Biopharma daily forecast for a month
Arbutus Biopharma Daily Price Targets
Arbutus Biopharma Stock Forecast 05-26-2022.
Pessimistic target level: 2.45
Optimistic target level: 2.54
Arbutus Biopharma Stock Forecast 05-27-2022.
Pessimistic target level: 2.43
Optimistic target level: 2.52
Arbutus Biopharma Stock Forecast 05-28-2022.
Pessimistic target level: 2.46
Optimistic target level: 2.51
Arbutus Biopharma Stock Forecast 05-29-2022.
Pessimistic target level: 2.44
Optimistic target level: 2.53
Arbutus Biopharma Stock Forecast 05-30-2022.
Pessimistic target level: 2.52
Optimistic target level: 2.58
Arbutus Biopharma Stock Forecast 05-31-2022.
Pessimistic target level: 2.47
Optimistic target level: 2.56
ABUS (ABUS) Monthly Stock Prediction for 2022
Arbutus Biopharma forecast for this year
Arbutus Biopharma Stock Prediction for Apr 2022
An uptrend is forecast for this month with an optimal target price of $3.03364. Pessimistic: $2.95. Optimistic: $3.19
Arbutus Biopharma Stock Prediction for May 2022
An uptrend is forecast for this month with an optimal target price of $3.25206. Pessimistic: $3.18. Optimistic: $3.42
Arbutus Biopharma Stock Prediction for Jun 2022
An uptrend is forecast for this month with an optimal target price of $3.29596. Pessimistic: $3.23. Optimistic: $3.49
Arbutus Biopharma Stock Prediction for Jul 2022
An downtrend is forecast for this month with an optimal target price of $3.26927. Pessimistic: $3.13. Optimistic: $3.48
Arbutus Biopharma Stock Prediction for Aug 2022
An downtrend is forecast for this month with an optimal target price of $2.9868. Pessimistic: $2.82. Optimistic: $3.17
Arbutus Biopharma Stock Prediction for Sep 2022
An downtrend is forecast for this month with an optimal target price of $2.94917. Pessimistic: $2.75. Optimistic: $3.15
Arbutus Biopharma Stock Prediction for Oct 2022
An downtrend is forecast for this month with an optimal target price of $2.9067. Pessimistic: $2.72. Optimistic: $3.12
Arbutus Biopharma Stock Prediction for Nov 2022
An uptrend is forecast for this month with an optimal target price of $2.93809. Pessimistic: $2.81. Optimistic: $3.08
Arbutus Biopharma Stock Prediction for Dec 2022
An uptrend is forecast for this month with an optimal target price of $3.04122. Pessimistic: $2.83. Optimistic: $3.14
Arbutus Biopharma (ABUS) Monthly Stock Prediction for 2023
Arbutus Biopharma (ABUS) Monthly Stock Prediction for 2024
Arbutus Biopharma (ABUS) Monthly Stock Prediction for 2025
Arbutus Biopharma (ABUS) Monthly Stock Prediction for 2026
Arbutus Biopharma information and performance
Arbutus Biopharma Corporation, a biopharmaceutical company, is engaged in the discovery, development and commercialization of a drug for patients with chronic hepatitis B virus (HBV) infection in the United States. Its HBV product portfolio consists of AB-836, a capsid inhibitor that can inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is undergoing preclinical studies. The company is also developing RNAi preparations that use the RNA interference pathway, which allows a new approach to the treatment of diseases.
Arbutus Biopharma Address
100-8900 GLENLYON PARKWAY, BURNABY, BC, CA
Market Capitalization: 352 485 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -71 643 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: N/A
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.344
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 8.42
Enterprise Value (EV) /Revenue
EV To EBITDA: -
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 148728000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.